Form D · Biotechnology
Inomagen Therapeutics, Inc.
Chicago, IL · CIK 0001626370
Offering snapshot reported Jun 20, 2025 · SEC filing
- Reported sold
- $140K Offering amount: $3.78M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 5, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 20, 2025 | Initial | $140,000 | No comparison | 4 | SEC filing |
| Apr 12, 2024 | Initial | $200,000 | No comparison | 4 | SEC filing |
| Nov 24, 2014 | Initial | $200,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-549400
Source: Form D, filed Jun 20, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rishi Arora | Director, Executive |
| Marc Penn | Director |
| James R. Vogler | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1375 W Fulton Street Ste 650
Chicago, IL, 60607
Chicago, IL, 60607